Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update
August 09, 2023 16:17 ET
|
Catalyst Pharmaceuticals, Inc.
Achieved Record Q2 2023 Total Net Revenues of $99.6 MillionAchieved FIRDAPSE® 2023 Second Quarter Net Revenues of $64.9 Million, a 22% Increase YOYAchieved 2023 Second Quarter GAAP EPS Diluted of...
Elevar Therapeutics Announces FDA Acceptance for Filing of New Drug Application for Rivoceranib in Combination with Camrelizumab as a First-line Treatment for Unresectable Hepatocellular Carcinoma
July 17, 2023 09:00 ET
|
Elevar Therapeutics
FORT LEE, N.J., July 17, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., and a fully integrated biopharmaceutical company dedicated to elevating...
Growth Report: Pre-Clinical CROs Market Worth $8.41 Billion, Worldwide Driven by Increasing Number of Clinical Trials During (2019-2027) | The Insight Partners
June 29, 2023 09:20 ET
|
The Insight Partners
Pune, India, June 29, 2023 (GLOBE NEWSWIRE) -- The Insight Partners’ latest study on "Pre Clinical CROs Market Size Report, Forecast to 2027 – COVID-19 Impact and Global Analysis – by Service, End...
HPQ Silica Polvere Inc. signe un accord de non-divulgation avec un important fabricant de silice pyrogénée
May 25, 2023 08:00 ET
|
Ressources HPQ Silicium inc.
MONTRÉAL, 25 mai 2023 (GLOBE NEWSWIRE) -- HPQ Silicium inc. (« HPQ » ou « la Société ») (TSX-V: HPQ) (OTCQX: HPQFF) (FRA: O08), une entreprise technologique spécialisée dans les procédés...
HPQ Silica Polvere Inc. Signs Non-Disclosure Agreement With Leading Fumed Silica Manufacturer
May 25, 2023 08:00 ET
|
HPQ Silicon Inc.
MONTREAL, May 25, 2023 (GLOBE NEWSWIRE) -- HPQ Silicon Inc. (“HPQ” or the “Company”) (TSX-V: HPQ) (OTCQX: HPQFF) (FRA: O08), a technology company specializing in green engineering processes for...
Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates
May 15, 2023 07:30 ET
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
May 10, 2023 08:00 ET
|
Minerva Neurosciences, Inc
FDA confirms acceptance of the filing of the NDA for roluperidone Application has been granted a standard review FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of February 26,...
Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update
May 09, 2023 16:02 ET
|
Arcutis Biotherapeutics, Inc.
Achieved net revenues of $2.8 million for ZORYVE® (roflumilast) cream 0.3% in the first quarter of 2023, with unit demand growth nearly doubling quarter-over-quarterContinued expansion of commercial...
Arcutis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
February 28, 2023 16:02 ET
|
Arcutis Biotherapeutics, Inc.
Achieved net revenues of $3.0 million for ZORYVE® (roflumilast) cream 0.3% in the first full quarter since the August 2022 launch, driven by continued unit demand growthSecured expanded commercial...
Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents
February 21, 2023 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Seborrheic dermatitis is an inflammatory skin disease affecting more than 10 million individuals in the United StatesIf approved, roflumilast foam would be the first topical drug for seborrheic...